Trial 0C-23-3


A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Mary Ordaz, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Niranjan Bhatt, D.M., Negeen Izadian, Coordinator, Celine Mazloum, D.M., Nazeli Livaskani, Coordinator, Stephanie Kim, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.